#United States #San Diego #Inhibrx #ozekibart #Chondrosarcoma

Inhibrx's FDA Milestone: A New Hope for Chondrosarcoma Patients

Inhibrx Biosciences, Inc., a biopharmaceutical company at the forefront of innovative cancer treatment, recently announced an important development: the acceptance of its Biologics License Application (BLA) by the U.S. Food and Drug Administration (FDA). This application seeks approval for Ozekibart (INBRX-109), designed specifically for patients battling unresectable or metastatic conventional chondrosarcoma, a rare and aggressive form of bone cancer.

This milestone was confirmed on June 15, 2026, with no filing review issues identified by the FDA, which has set a Prescription Drug User Fee Act (PDUFA) goal date of April 14, 2027. If granted approval, Ozekibart will become the first and only FDA-approved treatment for chondrosarcoma, signifying a significant breakthrough for a patient community that currently lacks approved systemic therapies.

Mark Lappe, the CEO of Inhibrx, expressed optimism about this achievement, highlighting the urgency and impact of Ozekibart on the chondrosarcoma community. He emphasized, “Chondrosarcoma is a devastating disease with no existing approved options, and we are eager to collaborate closely with the FDA to expedite the review process for this first-in-class targeted therapy.”

The Clinical Evidence Behind Ozekibart

The data supporting the BLA stems from the ChonDRAgon study, a rigorous randomized, blinded, placebo-controlled trial that assessed the efficacy of Ozekibart in treating patients with metastatic or unresectable conventional chondrosarcoma. The results were promising, demonstrating a significant enhancement in median progression-free survival (PFS). Patients treated with Ozekibart showed a 52% decrease in the risk of disease progression or death compared to those on a placebo, with median PFS extending to 5.52 months against 2.66 months for the placebo group.

These findings position Ozekibart as the first investigational therapy to show substantial PFS benefits in a randomized trial involving chondrosarcoma, especially as there are currently no approved systemic options available. This revelation holds a promise not only for improving patient outcomes but also for setting a new standard in treatment approaches for this underserved group.

Chondrosarcoma: A Quick Overview

Chondrosarcoma is classified as one of the most prevalent primary bone malignancies after osteosarcoma and primarily arises from cartilage cells within various bones, predominantly affecting the pelvis, hip, and shoulder areas. The difficulties in managing unresectable or metastatic chondrosarcoma are exacerbated by the tumor's resistance to conventional oncology treatments; hence, surgical resection is often the sole effective option for localized stages of the disease.

What is Ozekibart?

Ozekibart is a tetravalent death receptor 5 (DR5) agonist antibody engineered to induce tumor cell death through DR5 activation. This innovative approach leverages precise protein engineering techniques, aligning with Inhibrx’s commitment to creating targeted therapies that meet the specific needs of complex disease biology. Inhibrx has previously secured both Fast Track and orphan drug designations for Ozekibart from the FDA, highlighting the urgent clinical need and potential of this therapy.

The ongoing ChonDRAgon study encompassed 206 patients across 67 global sites, focusing on determining the drug’s efficacy in a controlled setting. During the trial, key enrollment criteria included patients with grade 2 or 3 unresectable or metastatic types of chondrosarcoma, ensuring the study's findings would accurately reflect the treatment's potential impact on those most affected by the disease.

Looking Ahead

As the FDA review process unfolds, Inhibrx continues to explore further applications for Ozekibart beyond chondrosarcoma, such as in combination treatments for Ewing sarcoma and colorectal cancer, where early signals reveal a high unmet medical need. With such comprehensive initiatives and strong clinical data, Inhibrx Biosciences is not just advancing its pipeline but also holding the potential to change patients’ lives radically.

In summary, the FDA’s acceptance of the BLA for Ozekibart represents a monumental step in providing hope to those suffering from severe forms of chondrosarcoma. As clinical trials reveal growing evidence of its efficacy, both patients and healthcare professionals eagerly await the possibilities this innovative therapeutic candidate could unlock.